Predicted protein targets (top 10)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | DGAT1 | O75907 | 2/20 | 0.35 |
| ▸ | CCR4 | P51679 | 2/20 | 0.32 |
| ▸ | EGFR | P00533 | 1/20 | 0.30 |
| ▸ | IGF1R | P08069 | 1/20 | 0.30 |
| ▸ | SRC | P12931 | 1/20 | 0.30 |
| ▸ | FLT4 | P35916 | 1/20 | 0.30 |
| ▸ | KDR | P35968 | 1/20 | 0.30 |
| ▸ | FLT3 | P36888 | 1/20 | 0.30 |
| ▸ | EPHB4 | P54760 | 1/20 | 0.30 |
| ▸ | TEK | Q02763 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL31411302 | 0.88 | DGAT1 (0.36) | DGAT1 | |
| SCHEMBL31411487 | 0.87 | DGAT1 (0.34) | DGAT1 | |
| SCHEMBL31411353 | 0.87 | CCR4 (0.34) | DGAT1CCR4EGFRIGF1RSRC | |
| SCHEMBL31411337 | 0.85 | DGAT1 (0.33) | DGAT1 | |
| SCHEMBL31411278 | 0.85 | SIGMAR1 (0.33) | DGAT1 | |
| SCHEMBL31411419 | 0.85 | SIGMAR1 (0.34) | DGAT1 | |
| SCHEMBL31411408 | 0.84 | DGAT1 (0.32) | DGAT1 | |
| SCHEMBL31411441 | 0.83 | DGAT1 (0.33) | DGAT1EGFRIGF1RSRCFLT4 | |
| SCHEMBL31411464 | 0.82 | DGAT1 (0.37) | DGAT1CCR4 | |
| SCHEMBL31411397 | 0.80 | DGAT1 (0.35) | DGAT1EGFRIGF1RSRCFLT4 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-4735425-A1 | COMPOUNDS | Psylo Pty Ltd (AU) | 2026-05-06 | — | — | EP | disclosed |
| US-20250353818-A1 | Compounds | Psylo Pty Ltd (AU) | 2025-11-20 | — | — | US | disclosed |
| US-12428380-B2 | Compounds | Psylo Pty Ltd (AU) | 2025-09-30 | — | — | US | disclosed |
| US-20250214943-A1 | Compounds | Psylo Pty Ltd (AU) | 2025-07-03 | — | — | US | disclosed |
| WO-2025000053-A1 | COMPOUNDS | Psylo Pty Ltd (AU) | 2025-01-02 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20250214943-A1 | Compounds | NLN, SLC18A2, PYGB | DGAT1 1102/4885CCR4 4209/4885EGFR 2960/4885 |
| US-12428380-B2 | Compounds | NLN, SLC18A2, PYGB | DGAT1 1102/4885CCR4 4209/4885EGFR 2960/4885 |
| US-20250353818-A1 | Compounds | NLN, SLC18A2, PYGB | DGAT1 1102/4885CCR4 4209/4885EGFR 2960/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.